Le Lézard
Classified in: Business
Subjects: ERN, CCA

Banco Macro Announces Results for the Fourth Quarter of 2017


BUENOS AIRES, Argentina, Feb. 19, 2018 /PRNewswire/ -- Banco Macro S.A. (NYSE: BMA; BCBA: BMA) ("Banco Macro" or "BMA" or the "Bank") announced today its results for the fourth quarter ended December 31, 2017 ("4Q17").  All figures are in Argentine pesos (Ps.) and have been prepared in accordance with Argentine GAAP.

Summary

? The Bank's net income totaled Ps.3.01 billion in 4Q17. This result was 16% higher than the Ps.2.60 billion posted in the third quarter of 2017 ("3Q17") and 78% higher than the result posted in the fourth quarter of 2016 ("4Q16"). In 4Q17, the accumulated annualized return on average equity ("ROAE") and the accumulated annualized return on average assets ("ROAA") were 28.6% and 5.2%, respectively. Net Income of Ps.9.39 billion in FY2017 was 44% higher than net income in FY2016.

? In 4Q17, Banco Macro's financing to the private sector grew 10% or Ps.11.7 billion quarter over quarter ("QoQ") totaling Ps.129.1 billion and increased 49% or Ps. 42.2 billion year over year ("YoY"). In the quarter, growth was driven by commercial loans, among which Documents and Others stand out, which grew 20% and 10% QoQ, respectively. Meanwhile within consumer loans, mortgage loans, credit cards and personal loans rose 29% and 16% and 12% QoQ, respectively.

? In 4Q17, the accumulated efficiency ratio reached 42.5%, lower than the 43.2% posted in 3Q17 and the 47.5% in 4Q16. Net fee income over administrative expenses was 56.8%, higher than the 53.8% registered in 4Q16.

? In 4Q17, Banco Macro's total deposits grew 6% QoQ, totaling Ps.144.2 billion and representing 80% of the Bank's total liabilities. Private sector deposits grew 9% QoQ.

? Banco Macro continued showing a strong solvency ratio, with excess capital of Ps.35.1 billion (28.1% regulatory capital ratio ? Basel III). In addition, the Bank's liquid assets remained at an adequate level, reaching 50.4% of its total deposits in 4Q17.

? In 4Q17, the Bank's non-performing to total financing ratio was 1.07% and the coverage ratio reached 183.14%.

4Q17 Earnings Release Conference Call
Wednesday, February 21, 2018
Time: 11:00 a.m. Eastern Time | 1:00 p.m. Buenos Aires Time

To participate, please dial:
Argentina Toll Free:
(0800) 444 2930

Participants Dial In (Toll Free):
+1 (844) 839 2185

Participants International Dial In:
+1 (412) 317 2506

With the presence of: Jorge Pablo Brito (Director), Gustavo Manriquez (CEO), Jorge Scarinci (CFO)

Conference ID: Banco Macro

Webcast: click here

Webcast Replay: click here
Available from 02/21/2018 through 03/07/2018

IR Contacts in Buenos Aires:
Jorge Scarinci
Chief Financial Officer

Nicolás A. Torres
Investor Relations

Phone: (54 11) 5222 6682
E-mail: [email protected]

Visit our website at: www.ri-macro.com.ar

SOURCE Banco Macro S.A.


These press releases may also interest you

at 11:00
Pomerantz LLP announces that a class action lawsuit has been filed against Checkpoint Therapeutics, Inc. ("Checkpoint" or the "Company") and certain officers. The class action, filed in the United States District Court for the Southern District of...

at 11:00
The Georgia Trust for Historic Preservation presented 26 awards recognizing the best of preservation in Georgia during its 47th annual Preservation Awards ceremony in Athens, Ga. Security Federal Bank in Augusta received the Marguerite Williams...

at 11:00
Pomerantz LLP is investigating claims on behalf of investors of Supernus Pharmaceuticals, Inc. ("Supernus" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980....

at 11:00
Pomerantz LLP announces that a class action lawsuit has been filed against VinFast Auto Ltd. ("VinFast" or the "Company") f/k/a Black Spade Acquisition Co., ("Black Spade") and certain officers. The class action, filed in the United States District...

at 11:00
Pomerantz LLP announces that a class action lawsuit has been filed against Ocugen, Inc. ("Ocugen" or the "Company") .  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext....

at 11:00
Pomerantz LLP announces that a class action lawsuit has been filed against Ventyx Biosciences, Inc. ("Ventyx" or the "Company") and certain officers.  The class action, filed in the United States District Court for the Southern District of...



News published on and distributed by: